We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ...

The study suggests a need for novel therapeutic approaches for patients with refractory disease or early relapse following CAR T-cell therapy. Despite limitations, BsAbs are considered safe and ...

The first part of the phase 2/3 study enrolled 40 people with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Participants received one of three doses of zilovertamab vedotin in ...

DiPersio is senior author of the team’s published report in Blood, titled “Phase 1/2 Trial of Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell malignancies.” ...

At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with ...

and in patients with refractory chronic cough (RCC), today announced additional analyses from the Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66). In March 2025 ...

GenTLE is a Phase I/IIa multi-center, open-label trial being conducted in the U.S. to evaluate the safety, tolerability and exploratory signs of efficacy of AMT-260 in individuals with refractory ...

CSIR NBRI Recruitment 2025: The CSIR-National Botanical Research Institute (NBRI) has released recruitment notification for Technical Assistant, Technician, Junior Secretariat Assistant (Finance ...